Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep;48(9):1115-1123.
doi: 10.1111/cup.14000. Epub 2021 Mar 15.

The utility of PRAME immunohistochemistry in the evaluation of challenging melanocytic tumors

Ahmed K Alomari  1   2 , Andrew W Tharp  1 , Brandon Umphress  1 , Rachel P Kowal  1
Affiliations

The utility of PRAME immunohistochemistry in the evaluation of challenging melanocytic tumors

Ahmed K Alomari et al. J Cutan Pathol. 2021 Sep.

Abstract

Background: PRAME (PReferentially expressed Antigen in Melanoma) immunohistochemistry has demonstrated high specificity for unequivocal melanomas; however, its utility in ambiguous melanocytic neoplasms has yet to be fully elucidated.

Methods: Cases of challenging melanocytic neoplasms were subclassified into one of three categories: challenging, favor benign (FB), challenging, cannot be subclassified (CCS), or challenging, favor malignant (FM). Using a previously published system, whereby cases with diffuse staining (>75%) were considered positive, scoring of PRAME was performed. Additionally, tumors with hotspot staining were also considered positive.

Results: Sixteen out of 85 tumors showed positive staining representing 5% of FB tumors, 24% of CCS tumors, and 47% of FM. In FB and CCS tumors, positive staining was mainly encountered in atypical intraepidermal melanocytic proliferations and spitzoid neoplasms. The specificity of positive PRAME staining was 95% and its concordance with the final diagnostic interpretation was 75%.

Conclusions: PRAME positivity is more common in neoplasms favored to be malignant by histopathologic evaluation. Its clinical utility may include early diagnosis of incipient melanoma in situ. Rarely, benign melanocytic neoplasms could show diffuse expression of PRAME, and additional studies are needed to determine optimal utilization. Lastly, hotspot staining may increase its sensitivity without much compromise in specificity.

Keywords: PRAME; immunocytochemistry; malignant melanoma; melanocytic lesions; melanocytic neoplasms.

PubMed Disclaimer

References

REFERENCES

    1. Rayess HM, Gupta A, Svider PF, et al. A critical analysis of melanoma malpractice litigation: should we biopsy everything? Laryngoscope. 2017;127(1):134-139.
    1. Brenn T. Melanocytic lesions - staying out of trouble. Ann Diagn Pathol. 2018;37:91-102.
    1. Alomari AK, Miedema JR, Carter MD, et al. DNA copy number changes correlate with clinical behavior in melanocytic neoplasms: proposal of an algorithmic approach. Mod Pathol. 2020;33(7):1307-1317.
    1. Alomari AK, Glusac EJ, Choi J, et al. Congenital nevi versus metastatic melanoma in a newborn to a mother with malignant melanoma - diagnosis supported by sex chromosome analysis and imaging mass spectrometry. J Cutan Pathol. 2015;42(10):757-764.
    1. Koh SS, Cassarino DS. Immunohistochemical expression of p16 in melanocytic lesions: an updated review and meta-analysis. Arch Pathol Lab Med. 2018;142(7):815-828.

MeSH terms

LinkOut - more resources